Optimizing Lutein Formulations for Targeted Ocular Drug Delivery: In Vitro and In Vivo Insights
Source abstract
Abstract
Lutein is a plant pigment beneficial for eye health and for preventing retinal-related diseases. However, lutein is unstable, with low oral bioavailability. In this study, lutein from Momordica cochinchinensis was loaded into cubosome lipid nanocarriers, both neutral (lutein-MO) and cationic (lutein-MO-DOTAP); the release, stability, and retinal penetration of the drug were improved. The formulation was biocompatible on retinal cells, showed sustained release in cell culture media and simulated lachrymal fluid, and was stable at 25 °C for 90 days. The cationic formulation, lutein-MO-DOTAP, showed greater uptake into retina cells than unencapsulated lutein and conferred greater protection of retina cells against H 2 O 2 stress. Lutein-MO-DOTAPs enhanced Nrf2 and HO-1 antioxidant genes and downregulated IL-6 inflammatory and VEGF-A angiogenesis genes. Lutein-MO-DOTAPs were detected in mice retina in vivo 1 day post intravitreal injection and 7 days after topical application as eyedrops. We have successfully created a more stable lutein formulation that could penetrate the back of the eye in the retina and be developed as a therapy to enhance eye health or mitigate eye diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Antioxidant Activity and Oxidative Stress · Retinoids in leukemia and cellular processes · Retinal Diseases and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Medicine
Deakin University
School of Science
RMIT University
School of Health and Biomedical Sciences
Centre for Eye Research Australia
The Royal Victorian Eye and Ear Hospital
Ophthalmology, Department of Surgery
The University of Melbourne
Funding
RMIT University · State Government of Victoria
References (70)
Show source-provided references
1. 10.1016/j.jff.2023.10559710.1016/j.jff.2023.105597 ↗
2. 10.3390/nu1206172110.3390/nu12061721 ↗
3. 10.12659/msm.90869910.12659/msm.908699 ↗
4. 10.1161/atvbaha.107.15143110.1161/atvbaha.107.151431 ↗
5. 10.26717/bjstr.2018.08.00169310.26717/bjstr.2018.08.001693 ↗
6. 10.1021/acsnano.2c0582410.1021/acsnano.2c05824 ↗
7. 10.1016/j.apmt.2021.10115610.1016/j.apmt.2021.101156 ↗
8. 10.1093/nutrit/nuz09610.1093/nutrit/nuz096 ↗
9. 10.1021/acsbiomaterials.0c0008510.1021/acsbiomaterials.0c00085 ↗
10. 10.1016/j.jcis.2021.02.02710.1016/j.jcis.2021.02.027 ↗
11. 10.1016/j.jcis.2022.04.0310.1016/j.jcis.2022.04.03 ↗
12. 10.2174/221030310866618062915034810.2174/2210303108666180629150348 ↗
13. 10.1021/acsami.0c2095610.1021/acsami.0c20956 ↗
14. 10.1248/cpb.c14-0031810.1248/cpb.c14-00318 ↗
15. 10.1007/s12247-021-09537-610.1007/s12247-021-09537-6 ↗
16. 10.1248/cpb.c14-0031810.1248/cpb.c14-00318 ↗
17. 10.1002/jps.2119010.1002/jps.21190 ↗
18. 10.1107/S002188981302774X10.1107/S002188981302774X ↗
19. 10.1021/ar300285u10.1021/ar300285u ↗
20. Armbruster D. A. · Clin. Biochem. Rev. · 2008 · 29 · 49
21. 10.1016/j.jddst.2019.04.03610.1016/j.jddst.2019.04.036 ↗
22. 10.1155/2024/359409910.1155/2024/3594099 ↗
23. 10.1021/acsomega.9b0114210.1021/acsomega.9b01142 ↗
24. 10.1093/nar/29.9.e4510.1093/nar/29.9.e45 ↗
25. 10.1006/abbi.2000.217110.1006/abbi.2000.2171 ↗
26. 10.1016/j.exer.2017.02.01610.1016/j.exer.2017.02.016 ↗
27. 10.1021/acsbiomaterials.0c0008510.1021/acsbiomaterials.0c00085 ↗
28. 10.3390/pharmaceutics1209079810.3390/pharmaceutics12090798 ↗
29. 10.1016/j.colsurfa.2016.04.03810.1016/j.colsurfa.2016.04.038 ↗
30. 10.3390/ph1603047410.3390/ph16030474 ↗
31. 10.1039/d0ra04971a10.1039/d0ra04971a ↗
32. 10.1080/10408398.2014.97026710.1080/10408398.2014.970267 ↗
33. 10.1016/j.foodhyd.2018.10.00310.1016/j.foodhyd.2018.10.003 ↗
34. 10.1111/ijfs.1339510.1111/ijfs.13395 ↗
35. 10.1016/j.foodres.2017.06.05510.1016/j.foodres.2017.06.055 ↗
36. 10.1016/j.ijbiomac.2020.02.10410.1016/j.ijbiomac.2020.02.104 ↗
37. 10.1371/journal.pone.019251110.1371/journal.pone.0192511 ↗
38. 10.5101/nbe.v1i1.p38-4910.5101/nbe.v1i1.p38-49 ↗
39. 10.1039/c6fd00039h10.1039/c6fd00039h ↗
40. 10.3390/app1011372210.3390/app10113722 ↗
41. 10.15416/ijcp.2015.4.4.28110.15416/ijcp.2015.4.4.281 ↗
42. 10.1371/journal.pone.019141510.1371/journal.pone.0191415 ↗
43. 10.1186/s11671-016-1471-010.1186/s11671-016-1471-0 ↗
44. 10.1016/j.ijpharm.2015.02.01210.1016/j.ijpharm.2015.02.012 ↗
45. 10.1038/s41467-019-12508-810.1038/s41467-019-12508-8 ↗
46. 10.3390/jfb502004310.3390/jfb5020043 ↗
47. 10.1016/j.micron.2006.08.00310.1016/j.micron.2006.08.003 ↗
48. 10.1248/bpb.30.35010.1248/bpb.30.350 ↗
49. 10.1021/acs.jafc.7b0192910.1021/acs.jafc.7b01929 ↗
50. 10.3390/antiox604010010.3390/antiox6040100 ↗
51. 10.1007/s00394-006-0635-610.1007/s00394-006-0635-6 ↗
52. 10.1038/s41419-019-2182-010.1038/s41419-019-2182-0 ↗
53. 10.1016/j.colsurfb.2021.11156410.1016/j.colsurfb.2021.111564 ↗
54. 10.1016/j.biopha.2017.06.09310.1016/j.biopha.2017.06.093 ↗
55. 10.1016/j.xphs.2021.02.00710.1016/j.xphs.2021.02.007 ↗
56. 10.1124/pr.117.01475310.1124/pr.117.014753 ↗
57. 10.1038/s41419-020-02950-810.1038/s41419-020-02950-8 ↗
58. 10.1002/mnfr.20150010910.1002/mnfr.201500109 ↗
59. 10.3389/fphar.2020.0084410.3389/fphar.2020.00844 ↗
60. 10.1016/j.exer.2016.02.01310.1016/j.exer.2016.02.013 ↗
61. 10.1016/j.imbio.2010.05.02510.1016/j.imbio.2010.05.025 ↗
62. Wu W.-C. · Mol. Vis. · 2010 · 16 · 1864
63. 10.1155/2020/790127010.1155/2020/7901270 ↗
64. 10.1016/S1350-9462(02)00043-510.1016/S1350-9462(02)00043-5 ↗
65. 10.1002/advs.20230217410.1002/advs.202302174 ↗
66. 10.1016/j.ophtha.2012.09.00610.1016/j.ophtha.2012.09.006 ↗
67. 10.1097/iae.0b013e3181a94f0110.1097/iae.0b013e3181a94f01 ↗
68. 10.1124/jpet.119.25693310.1124/jpet.119.256933 ↗
69. 10.1186/s12951-023-01992-210.1186/s12951-023-01992-2 ↗
70. 10.1080/17425255.2020.180327810.1080/17425255.2020.1803278 ↗